To overcome these barriers, many siRNA delivery systems have been developed. Among these, lipid-based nanoparticles have great potential owing to their biocompatibility and low toxicity in ...

Small interfering RNA (siRNA) molecules hold immense potential for treating diseases by silencing specific genes. Encapsulated in lipid nanoparticles (LNPs), siRNA can be delivered efficiently to ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic ...

Take high LDL cholesterol as an example ... In theory, we could design a small interfering RNA (siRNA)—the active ingredient ...

Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes, but our bodies also need cholesterol to survive.

siRNA therapeutics have already been validated ... the liver is currently often targeted is due to the fact that the lipid nanoparticles used for delivery typically accumulate in the organ when ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

A recent study found that the method of mixing siRNA with lipid nanoparticles (LNPs) is key to success. siRNA therapies show promise for treating diseases like cancer and genetic disorders ...

Stable nucleic acid lipid particle formulations in systemic delivery Target siRNA and modification (yes/no) Animal model Ref. DSPC:Chol:PEG–C–DMA:DLin–DMA (20:48:2:30)–siRNA Hepatitis B ...

The methods included pre-mixing, where siRNA and lipids were combined using a microfluidic mixer; post-mixing (A), where siRNA was mixed with empty LNPs in an acidic condition with ethanol; and ...